INTRODUCTION: EGFR (epidermal growth factor receptor), cyclin D1 and Akt/mTOR pathways are active in head and neck cancer. The aim of this study was to explore biomarker expression, their correlations with clinicopathological parameters and their prognostic utility in a cohort of patients with localized squamous laryngeal carcinoma. PATIENTS AND METHODS: We assessed relative messenger RNA expression of EGFR, Akt1, 2, and 3, mTOR and CCND1, copy number variants of the EGFR and CCND1 genes and immunohistochemical protein expression of EGFR, p-Akt308, p-Akt473, pmTOR, PTEN, p53 and cyclin D1 in paraffin-embedded tissue samples of localized laryngeal carcinomas. RESULTS: In 289 patients with T3-4 (77.8%), node-negative (84.1%) tumors of the larynx, high EGFR and CCND1 mRNA correlated with no or ex-smoking, (p = 0.003 and p = 0.029, respectively), while low Akt3 mRNA correlated with alcohol abuse, N0 stage, total laryngectomy, and absence of neck dissection. At a median follow-up of 74.5 months, high mTOR mRNA expression was marginally associated with shorter disease-free survival (hazard ratio [HR] = 1.54; p = 0.093) and high Akt3 mRNA with shorter overall survival (HR = 1.49; p = 0.0786), in univariate analysis. In multivariate analysis, node-positive status, subglottic-transglottic location, surgery other than total laryngectomy and mTOR/CCND1 mRNA interaction with a hazard ratio of 2.16 (p value for interaction: 0.0010) were independent predictors of relapse, while node-positive status and subglottic-transglottic location were associated with higher risk for death. CONCLUSION: In localized laryngeal cancer, clinicopathological parameters and an interaction of high mTOR and CCND1 mRNA expression were found to be associated with poor patient outcome.
INTRODUCTION:EGFR (epidermal growth factor receptor), cyclin D1 and Akt/mTOR pathways are active in head and neck cancer. The aim of this study was to explore biomarker expression, their correlations with clinicopathological parameters and their prognostic utility in a cohort of patients with localized squamous laryngeal carcinoma. PATIENTS AND METHODS: We assessed relative messenger RNA expression of EGFR, Akt1, 2, and 3, mTOR and CCND1, copy number variants of the EGFR and CCND1 genes and immunohistochemical protein expression of EGFR, p-Akt308, p-Akt473, pmTOR, PTEN, p53 and cyclin D1 in paraffin-embedded tissue samples of localized laryngeal carcinomas. RESULTS: In 289 patients with T3-4 (77.8%), node-negative (84.1%) tumors of the larynx, high EGFR and CCND1 mRNA correlated with no or ex-smoking, (p = 0.003 and p = 0.029, respectively), while low Akt3 mRNA correlated with alcohol abuse, N0 stage, total laryngectomy, and absence of neck dissection. At a median follow-up of 74.5 months, high mTOR mRNA expression was marginally associated with shorter disease-free survival (hazard ratio [HR] = 1.54; p = 0.093) and high Akt3 mRNA with shorter overall survival (HR = 1.49; p = 0.0786), in univariate analysis. In multivariate analysis, node-positive status, subglottic-transglottic location, surgery other than total laryngectomy and mTOR/CCND1 mRNA interaction with a hazard ratio of 2.16 (p value for interaction: 0.0010) were independent predictors of relapse, while node-positive status and subglottic-transglottic location were associated with higher risk for death. CONCLUSION: In localized laryngeal cancer, clinicopathological parameters and an interaction of high mTOR and CCND1 mRNA expression were found to be associated with poor patient outcome.
Authors: D Aguirre; P Boya; D Bellet; S Faivre; F Troalen; J Benard; P Saulnier; S Hopkins-Donaldson; U Zangemeister-Wittke; G Kroemer; E Raymond Journal: Apoptosis Date: 2004-11 Impact factor: 4.677
Authors: P Skarlos; C Christodoulou; K T Kalogeras; A G Eleftheraki; M Bobos; A Batistatou; C Valavanis; O Tzaida; E Timotheadou; R Kronenwett; R M Wirtz; I Kostopoulos; D Televantou; E Koutselini; I Papaspirou; C A Papadimitriou; D Pectasides; H Gogas; G Aravantinos; N Pavlidis; P Arapantoni; D V Skarlos; G Fountzilas Journal: Cancer Chemother Pharmacol Date: 2011-09-08 Impact factor: 3.333
Authors: Kolja Freier; Stefan Joos; Christa Flechtenmacher; Frauke Devens; Axel Benner; Franz X Bosch; Peter Lichter; Christof Hofele Journal: Cancer Res Date: 2003-03-15 Impact factor: 12.701
Authors: Arno Olthoff; Andreas Ewen; Hendrik Andreas Wolff; Robert Michael Hermann; Hilke Vorwerk; Andrea Hille; Ralph Rödel; Clemens F Hess; Wolfgang Steiner; Olivier Pradier; Hans Christiansen Journal: Strahlenther Onkol Date: 2009-05-15 Impact factor: 3.621
Authors: Anthony Kong; Pierre Leboucher; Russell Leek; Véronique Calleja; Stuart Winter; Adrian Harris; Peter J Parker; Banafshé Larijani Journal: Cancer Res Date: 2006-03-01 Impact factor: 12.701
Authors: Marco Lionello; A Lovato; A Staffieri; S Blandamura; C Turato; L Giacomelli; C Staffieri; G Marioni Journal: Eur Arch Otorhinolaryngol Date: 2013-09-25 Impact factor: 2.503
Authors: F Hoebers; E Rios; E Troost; P van den Ende; K Kross; M Lacko; R Lalisang; B Kremer; J de Jong Journal: Strahlenther Onkol Date: 2013-08-24 Impact factor: 3.621
Authors: Elena Fountzilas; Vassiliki Kotoula; Nikolaos Angouridakis; Ilias Karasmanis; Ralph M Wirtz; Anastasia G Eleftheraki; Elke Veltrup; Konstantinos Markou; Angelos Nikolaou; Dimitrios Pectasides; George Fountzilas Journal: PLoS One Date: 2013-08-09 Impact factor: 3.240